[MCCARTY, Tomas David, MCCARTY, Tomas David, MOORE, William Edward, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, BERTSCHE, Michael Wayne, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, BERTSCHE, Michael Wayne, WRIGHT, Edward Joseph, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, BERTSCHE, Michael Wayne, WRIGHT, Edward Joseph, KANAKAGIRI, Anand, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, BERTSCHE, Michael Wayne, WRIGHT, Edward Joseph, KANAKAGIRI, Anand, DAVE, Pratik, MCCARTY, Tomas David, MOORE, William Edward, CLARK, Michael Bruce, KATZ, Jeffrey Stanton, BERTSCHE, Michael Wayne, WRIGHT, Edward Joseph, KANAKAGIRI, Anand, DAVE, Pratik, PENNER, Janis] Mythenquai 50/60CH-8022 Zürich Proposed are an automated, distinct-channel-based automated mortality classification system and a method for the automated assessment, measurement, and monitoring of preferred life risks, wherein life-risks associated with risk exposed individuals (31, 32, 33) are transferable to a first insurance system (2) and/or from the first insurance system (2) to an associated second insurance system (3). The system (1) comprises a table (10) with retrievable stored risk classes (101, 102, 103) each comprising assigned, triggerable risk class criteria (110, 111, 112). Individual-specific parameters (311, 321, 331) of the risk exposed individuals (31, 32, 33) are captured relating to criteria (110, 111, 112) of the stored risk classes (101, 102, 103) and a specific risk class (101, 102, 103) associated with the risk of the exposed individual (31, 32, 33) is identified out and selected of said stored risk classes (101, 102, 103) based on the captured parameters (311, 321, 331). The system (1) comprises a selectable first channel (21) providing a possible movement of specific single or select combination impairment risks not matching any class criteria to an accepted risk class, a selectable second channel (22) providing the movement of risks between different categorizations, thereby dynamically reclassify risks on a mortality consistent basis, and a selectable third channel (23) providing automated assessment of a risk decline. Proposed are an automated, distinct-channel-based automated mortality classification system and a method for the automated assessment, measurement, and monitoring of preferred life risks, wherein life-risks associated with risk exposed individuals (31, 32, 33) are transferable to a first insurance system (2) and/or from the first insurance system (2) to an associated second insurance system (3). The system (1) comprises a table (10) with retrievable stored risk classes (101, 102, 103) each comprising assigned, triggerable risk class criteria (110, 111, 112). Individual-specific parameters (311, 321, 331) of the risk exposed individuals (31, 32, 33) are captured relating to criteria (110, 111, 112) of the stored risk classes (101, 102, 103) and a specific risk class (101, 102, 103) associated with the risk of the exposed individual (31, 32, 33) is identified out and selected of said stored risk classes (101, 102, 103) based on the captured parameters (311, 321, 331). The system (1) comprises a selectable first channel (21) providing a possible movement of specific single or select combination impairment risks not matching any class criteria to an accepted risk class, a selectable second channel (22) providing the movement of risks between different categorizations, thereby dynamically reclassify risks on a mortality consistent basis, and a selectable third channel (23) providing automated assessment of a risk decline.

[BEATON, Graham, BEATON, Graham, TUCCI, Fabio C., BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., MCHARDY, Stanton F., BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., MCHARDY, Stanton F., RUIZ, Francisco Xavier, III, BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., MCHARDY, Stanton F., RUIZ, Francisco Xavier, III, LOPEZ, Ambrosio, Jr., BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., MCHARDY, Stanton F., RUIZ, Francisco Xavier, III, LOPEZ, Ambrosio, Jr., CAMPOS, Bismarck, BEATON, Graham, TUCCI, Fabio C., RAVULA, Satheesh B., MCHARDY, Stanton F., RUIZ, Francisco Xavier, III, LOPEZ, Ambrosio, Jr., CAMPOS, Bismarck, WANG, Hua-Yu Leo] 1624 Headway CircleSuite 100Austin, Texas 78754 Described herein are compounds and pharmaceutical compositions containing such compounds, which inhibit the activity of Olig2. Also described herein are methods of using such Olig2 inhibitors, alone and in combination with other compounds, for treating cancer and other diseases. In particular the Olig2 inhibitors may be used to treat glioblastoma.

[STANTON, Briden Ray, STANTON, Briden Ray, BECKWITH, Ashley L., STANTON, Briden Ray, BECKWITH, Ashley L., HAWS, Hilary R., STANTON, Briden Ray, BECKWITH, Ashley L., HAWS, Hilary R., NOREN, Dalton A., STANTON, Briden Ray, BECKWITH, Ashley L., HAWS, Hilary R., NOREN, Dalton A., PICKRELL, Joshua] 10811 West Collins AvenueLakewood, Colorado 80215 Embodiments of methods and systems are described for automating protein production from genetically modified microorganisms. Embodiments provide for growing modified microorganisms to generate protein, releasing the protein and recovering the protein automatically. Also described are embodiments for lysing cells that may be used to as part of an automated system to recover the protein after generation by the microorganisms. Embodiments of methods and systems are described for automating protein production from genetically modified microorganisms. Embodiments provide for growing modified microorganisms to generate protein, releasing the protein and recovering the protein automatically. Also described are embodiments for lysing cells that may be used to as part of an automated system to recover the protein after generation by the microorganisms.

[BELLEY, Matthew, D., BELLEY, Matthew, D., THEREIN, Michael, J., BELLEY, Matthew, D., THEREIN, Michael, J., STANTON, Ian, N., BELLEY, Matthew, D., THEREIN, Michael, J., STANTON, Ian, N., YOSHIZUMI, Terry, T., BELLEY, Matthew, D., THEREIN, Michael, J., STANTON, Ian, N., YOSHIZUMI, Terry, T., LANGLOSS, Brian, W., BELLEY, Matthew, D., THEREIN, Michael, J., STANTON, Ian, N., YOSHIZUMI, Terry, T., LANGLOSS, Brian, W., CRACIUNESCU, Oana, I., BELLEY, Matthew, D., THEREIN, Michael, J., STANTON, Ian, N., YOSHIZUMI, Terry, T., LANGLOSS, Brian, W., CRACIUNESCU, Oana, I., CHINO, Junzo, P.] 2812 Erwin RoadDurham, NC 27705 The present disclosure provides systems and methods for verifying radiation source delivery in brachytherapy by allowing for the radiation source location and dwell time to be determined via real-time measurement. In an embodiment, a radiation detector may be disposed proximate to a radiotherapy target. The radiation detector is configured to provide real-time information indicative of ionizing radiation emitted by a radiation source. A controller may perform operations including receiving, from the radiation detector, real-time information indicative of at least one of: a particle flux rate, an energy fluence, or an absorbed dose of ionizing radiation emitted from the radiation source. The operations may also include determining, based on the received information, at least one of: a location of the radiation source or a dwell time of the radiation source.

[GREGERSON, Eugene A., GREGERSON, Eugene A., SEBRING, Paul, GREGERSON, Eugene A., SEBRING, Paul, STANTON, Russell, GREGERSON, Eugene A., SEBRING, Paul, STANTON, Russell, COPPEN, Scott, GREGERSON, Eugene A., SEBRING, Paul, STANTON, Russell, COPPEN, Scott, HARRIS, Adeline, GREGERSON, Eugene A., SEBRING, Paul, STANTON, Russell, COPPEN, Scott, HARRIS, Adeline, FURLONG, Todd, GREGERSON, Eugene A., SEBRING, Paul, STANTON, Russell, COPPEN, Scott, HARRIS, Adeline, FURLONG, Todd, BAKER, Jeff] 2 Shaker Road, Building F, Suite 100Shirley, Massachusetts 01464 Methods and systems for performing robotically-assisted surgery in conjunction with intra-operative imaging. A method includes moving a robotic arm with respect to a patient and an imaging device to move an end effector of the robotic arm to a pre-determined position and orientation with respect to the patient based on imaging data of the patient obtained by the imaging device. The robotic arm maintains the end effector in the pre-determined position and orientation with respect to the patient and does not collide with the imaging device or with the patient when the imaging device moves with respect to the patient. Methods and systems for performing robotically-assisted surgery in conjunction with intra-operative imaging. A method includes moving a robotic arm with respect to a patient and an imaging device to move an end effector of the robotic arm to a pre-determined position and orientation with respect to the patient based on imaging data of the patient obtained by the imaging device. The robotic arm maintains the end effector in the pre-determined position and orientation with respect to the patient and does not collide with the imaging device or with the patient when the imaging device moves with respect to the patient.

[ROWE, Stanton, J., ROWE, Stanton, J., LEE, Jinny, ROWE, Stanton, J., LEE, Jinny, CORSO, Phillip P., Jr., ROWE, Stanton, J., LEE, Jinny, CORSO, Phillip P., Jr., CHAU, Mark, ROWE, Stanton, J., LEE, Jinny, CORSO, Phillip P., Jr., CHAU, Mark, HAUSER, Davis, L.] One Edwards WayIrvine, CA 92614 The present disclosure concerns embodiments of an implantable device that are used to treat an insufficient heart valve that has been previously treated by implantation of a fixation device or an Alfieri stitch that is secured to opposing portions of the native leaflets. In one representative embodiment, an implantable device for remodeling a native mitral valve having two native leaflets and a fixation device or an Alfieri stitch secured to respective free edges of the leaflets is configured to be coupled to the fixation device or Alfieri stitch and apply a remodeling force to the native mitral valve that draws the native leaflets toward each other to promote coaptation of the leaflets. The present disclosure concerns embodiments of an implantable device that are used to treat an insufficient heart valve that has been previously treated by implantation of a fixation device or an Alfieri stitch that is secured to opposing portions of the native leaflets. In one representative embodiment, an implantable device for remodeling a native mitral valve having two native leaflets and a fixation device or an Alfieri stitch secured to respective free edges of the leaflets is configured to be coupled to the fixation device or Alfieri stitch and apply a remodeling force to the native mitral valve that draws the native leaflets toward each other to promote coaptation of the leaflets.

[FRANKENBACH, Gayle, Marie, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, MADHAV, Prakash, J., FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, MADHAV, Prakash, J., STANTON, David, Thomas, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, MADHAV, Prakash, J., STANTON, David, Thomas, READNOUR, Christine, Marie, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, MADHAV, Prakash, J., STANTON, David, Thomas, READNOUR, Christine, Marie, LIU, Zaiyou, FRANKENBACH, Gayle, Marie, HOLLINGSHEAD, Judith, Ann, HORENZIAK, Steven, Anthony, MADHAV, Prakash, J., STANTON, David, Thomas, READNOUR, Christine, Marie, LIU, Zaiyou, CETTI, Jonathan, Robert] One Procter & Gamble PlazaCincinnati, Ohio 45202 The present invention relates to malodor reduction compositions and methods of making and using same. The malodor reduction compositions are suitable for use in a variety of applications, including use in consumer products, for example, air freshening compositions, laundry detergents, fabric enhancers, surface cleaners, beauty care products, dish care products, diapers, feminine protection articles, and plastic films for garbage bags. Such malodor control technologies do not unduely interfere with the scent of the perfumed or unperfumed situs that is treated with the malodor control technology.

[ROSS, Stanton, E., ROSS, Stanton, E., HAN, Peng, ROSS, Stanton, E., HAN, Peng, DICK, Jeremy, A.] 9705 Loiret BoulevardLenexa, Kansas 66219 At a high level, embodiments of the invention relate to augmenting video data with presence data derived from one or more proximity tags. More specifically, embodiments of the invention generate forensically authenticated recordings linking video imagery to the presence of specific objects in or near the recording. One embodiment of the invention includes video recording system comprising a camera, a wireless proximity tag reader, a storage memory and control circuitry operable to receive image data from the camera receive a proximity tag identifier identifying a proximity tag from the proximity tag reader, and store an encoded frame containing the image data and the proximity tag identity in the storage memory.

[WEAVER, Stanton Earl, WEAVER, Stanton Earl, BRAY, James William, WEAVER, Stanton Earl, BRAY, James William, BOWMAN, Michael John] 1 River RoadSchenectady, NY 12345 A submersible liquid-vapor generator (LVG) includes an evaporator portion in heat transfer communication with a heat energy source. The LVG also includes a magnetic field apparatus coupled in flow communication with the evaporator portion. The LVG further includes a condenser portion coupled in flow communication with the magnetic field apparatus. The LVG also includes a hybrid working fluid including nanoparticles. The evaporator portion, the magnetic field portion, and the condenser portion at least partially define a hybrid working vapor flow path. The LVG further includes an electrically non-conductive wick structure coupled in flow communication with the evaporator portion and the condenser portion. The wick structure at least partially defines a hybrid working liquid flow path extending between the condenser portion and the evaporator portion.

[MARKOWITZ, Sanford, MARKOWITZ, Sanford, GERSON, Stanton, MARKOWITZ, Sanford, GERSON, Stanton, DESAI, Amar, MARKOWITZ, Sanford, GERSON, Stanton, DESAI, Amar, HO, Won Jin] 10900 Euclid AvenueCleveland, Ohio 44106 A method of treating or preventing a fibrotic disease, disorder or condition includes administering to a subject in need of treatment a 15-PGDH inhibitor.